[Translated article] Practical Update of the Recommendations Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis with Biologic Therapy. Part 1. Concepts and General Management of Psoriasis With Biologic Therapy

Carrascosa, J.M.; Puig, Lluís; Belinchón, Isabel; Salgado‐Boquete, Laura; Alcázar, E. del; Lencina, Juan José Andrés; Moreno, Daniel; Cueva, Pablo de la

doi:10.1016/j.ad.2021.10.011

Cited by 12 publications

(17 citation statements)

References 139 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Absolute PASI significantly decreased from 10.5 to 4.8, 1.9 and 1.3 at weeks 12, 24, and 52, respectively. Bearing in mind PASI < 2 may be the ideal goal in the daily clinical setting, 22 we analyzed absolute PASI and, PASI < 2 was achieved by 52%, 77%, and 88% of the patients after 12, 24, and 52 weeks of guselkumab treatment, respectively.…”

Section: Resultsmentioning

confidence: 99%

“…Most patients (90%) received guselkumab as monotherapy and washout period varied according the schedule of the prior biologic treatment. The decision to start guselkumab due to poor control of PsO in most cases with the prior biological treatment was founded by not achieving a Psoriasis area severity index (PASI)75 response, having an absolute PASI ≥ 5 or a DLQI greater than 10, according to the recommendations established in the Spanish guidelines for the management or switching of biologicals 22 . Decision about treatment failure (in cutaneous and/or joint domains) was done in the multidisciplinary unit, as well, where rheumatologist evaluated activity in PsA in all cases.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Guselkumab effectiveness and survival in patients with psoriasis and psoriatic arthritis: Multicenter analysis in daily clinical practice by the Spanish Psoriasis Group

Rocamora

Crespi

Ferrán

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

Guselkumab is a monoclonal antibody that selectively blocks the p19 subunit of interleukin 23 and has been approved for the treatment of moderate to severe psoriasis and active psoriatic arthritis in adult patients due to its efficacy in different clinical trials. Therefore, itis important to know the performance of guselkumab in this setting of patients in clinical practice given that a high percentage of them are not represented in these clinical trials. Our objective was to evaluate the effectiveness and tolerability of guselkumab in clinical practice in the first patients with psoriasis and psoriatic arthritis treated since the date of its approval for psoriasis in Spain, in joint dermatology-rheumatology clinics. A multicenter retrospective data collection was carried out, in which 14 hospitals participated, including a total of 90 patients with psoriatic arthritis confirmed by a rheumatologist. Data collection was recorded at baseline and at weeks 12, 24, and 52 for both the articular and cutaneous domains.Ninety PsA patients started treatment with guselkumab and therefore were included in this study. The vast majority had already failed to at least to one biologic therapyprior guselkumab prescription. The median age was 55 years, 61% were female and 46% had a BMI ≥ 30 kg/m 2 . Sixty-nine percent suffered from peripheral arthritis, and in 34% an axial involvement was also detected; dactylitis or enthesitis was present in 24% and 29% of patients, respectively. Guselkumab was effective in controlling both articular and skin manifestations of PsA patients. Absolute PASI significantly decreased from 10.5 to 4.8, 1.9 and 1.3 at weeks 12, 24, and 52, respectively. In 29 out of 61 (48%) of cases, DAPSA was moderate or high, and patients showed a significant reduction in DAPSA at 12, 24, and 52 weeks of treatment (mean DAPSA values at baseline and follow up were 29, 20, 16, and 14, respectively). Patients with DAPSA in low activity or in remission at the time of initiation of guselkumab maintained Vicenç Rocamora and Fernando Gallardo contributed equally to this work.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Guselkumab effectiveness and survival in patients with psoriasis and psoriatic arthritis: Multicenter analysis in daily clinical practice by the Spanish Psoriasis Group

Rocamora

Crespi

Ferrán

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…Despite these rapid advancements, other issues have risen, such as factors that can affect treatment selection, including insurance systems and health care leaders in the hospital. 12 Moreover, with the rapid advancements in biological agents, investigators have begun paying more attention into exploring other outcomes. For example, a previous study reported that TNF-alpha inhibitors may exhibit stronger suppressive properties on inflammatory markers, whereas newer interleukin inhibitors agents may exhibit favorable safety profiles.…”

Section: Discussionmentioning

confidence: 99%

Rapid Response of Palmoplantar Psoriasis to Risankizumab: A Case Report

Muqrin¹,

Alghamdi²,

Alshaalan³

2022

CCID

View full text Add to dashboard Cite

Palmoplantar psoriasis, a clinical variant of plaque psoriasis, has a significant impact by causing deterioration in the social and functional aspects of patients’ lives. Numerous therapeutic interventions are available for palmoplantar psoriasis. Although emerging biological agents have had an enormous positive impact on chronic plaque psoriasis, studies assessing their effectiveness in the palmoplantar phenotype are limited in the literature. We therefore present a case report of a patient with a 10-year history of palmoplantar psoriasis, which has significantly impacted her occupational life. She was treated with Risankizumab, showing a significant and rapid improvement in her symptoms. We believe that Risankizumab could be one of the most effective therapeutic interventions in the clinical context where rapid clearance of palmoplantar psoriasis is required.

show abstract

“…Clinical response to ustekinumab treatment was assessed using absolute PASI at the extraction time of serum sampling. Optimal response was defined to PASI values ≤ 3, according to our previous studies ( 5 , 9 ), and treatment goal (Physician’s Global Assessment of clear or nearly clear and/or PASI < 2) in the British Association of Dermatologists’ guidelines for biologic therapy for psoriasis and practical update of the recommendations published by the psoriasis group of the Spanish Academy of Dermatology and Venereology on the treatment of psoriasis with biologic therapy ( 1 , 10 ).…”

Section: Methodsmentioning

confidence: 99%

Real-world use of ustekinumab therapeutic drug monitoring in moderate to severe psoriasis

et al. 2022

View full text Add to dashboard Cite

IntroductionThere is growing evidence that therapeutic drug monitoring of biologic therapy is beneficial in psoriatic patients. With respect to ustekinumab, the available evidence has not shown any relationship yet. The objective of this study is to identify correlations among ustekinumab trough concentrations, anti-ustekinumab antibodies and clinical response in moderate-to-severe plaque psoriasis patients, in a real-world setting.MethodsObservational prospective follow-up study in psoriatic patients treated with ustekinumab. Patients were classified in optimal (PASI ≤ 3) and suboptimal responders (PASI > 3). Mann–Whitney U test and Spearman’s rank correlation coefficient were used. Receiver-operator characteristic curve analysis was performed to identify ustekinumab concentration cut-off to achieve optimal response. A p-value < 0.05 was considered statistically significant.ResultsA total of 59 patients were included. Forty-eight patients (81.4%) corresponded to optimal responders and 11 (18.6%) to suboptimal responders. There was significant difference to ustekinumab concentrations: 0.7 μg/mL (range <0.1–1.8) vs. 0.4 μg/mL (range <0.1–0.8) respectively (p = 0.007). Positive correlation between ustekinumab concentration and psoriasis area and severity index (PASI) value was detected (p = 0.009). A cut-off value of 0.6 μg/mL ustekinumab concentration was found to achieve clinical response. Anti-ustekinumab antibodies were detected in 2 (3.4%) samples, both suboptimal responders.ConclusionA positive correlation exits between ustekinumab concentration and clinical response (optimal response PASI values ≤ 3) in blood draws performed before drug administration. The measurement of anti-ustekinumab antibodies could be considered in treatment failure.

show abstract

[Translated article] Practical Update of the Recommendations Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis with Biologic Therapy. Part 1. Concepts and General Management of Psoriasis With Biologic Therapy

Cited by 12 publications

References 139 publications

Guselkumab effectiveness and survival in patients with psoriasis and psoriatic arthritis: Multicenter analysis in daily clinical practice by the Spanish Psoriasis Group

Guselkumab effectiveness and survival in patients with psoriasis and psoriatic arthritis: Multicenter analysis in daily clinical practice by the Spanish Psoriasis Group

Rapid Response of Palmoplantar Psoriasis to Risankizumab: A Case Report

Real-world use of ustekinumab therapeutic drug monitoring in moderate to severe psoriasis

Contact Info

Product

Resources

About